جستجوی استاد راهنمای دانشگاهی

• Developmental Biology
• Neurosciences
• Dopamine Neurons
• +۴ مورد دیگر

Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.

David S. Eisenbergمشاهده پروفایل

استاد

• Protein Aggregation
• Amyloid Structures
• Prion Diseases
• +۵ مورد دیگر

David S. Eisenberg is a Professor of Chemistry and Biochemistry and Biological Chemistry at the University of California, Los Angeles, where he also serves as Director of the UCLA-DOE Institute for Genomics and Proteomics and as an HHMI Investigator. His research focuses on protein interactions, particularly the structural basis for conversion of normal proteins to the amyloid state and conversion of prions to the infectious state. Dr. Eisenberg earned his undergraduate degree in biochemical sciences from Harvard College and his D.Phil. degree in theoretical chemistry from Oxford University on a Rhodes Scholarship. His postdoctoral research was on ice and water with Walter Kauzmann at Princeton and in protein crystallography with Richard Dickerson. He joined the UCLA faculty after his postdoctoral studies. Dr. Eisenberg and his research group focus on protein interactions in amyloid and prion diseases. These diseases involve protein aggregation where normal functional proteins convert to abnormal aggregated forms. Systemic amyloid diseases like dialysis-related amyloidosis result from fiber accumulation until organ failure, while neurodegenerative diseases like Alzheimer's, Parkinson's, ALS, and prion conditions appear to be caused by smaller oligomers. In 2005, his team determined the atomic-level structure for the amyloid fiber spine, revealing a 'steric zipper' of two parallel beta sheets packed across a dry interface. Since then, they've determined approximately 90 amyloid spines from 15 disease-related proteins. In 2010, they identified the structure of a toxic amyloid-related oligomer consisting of six anti-parallel beta strands forming a cylindrical barrel. His recent publications demonstrate continued innovation in amyloid research, with focus areas including structural prediction of amyloid formation, mechanisms of tau fibril disassembly in Alzheimer's disease, cryo-EM analysis of amyloid polymorphism, and structure-based design of inhibitors for amyloid toxicity. His work integrates computational, structural, and biochemical approaches to understand protein aggregation across multiple disease contexts. Dr. Eisenberg has received numerous prestigious awards and honors: National Academy of Sciences Member American Philosophical Society Member Institute of Medicine Member Howard Hughes Medical Institute Investigator Biophysical Society Emily M. Gray Award Harvard Westheimer Medal UCLA Seaborg Medal Technion - Israel Institute of Technology Harvey Prize in Human Health As Director of the UCLA-DOE Institute for Genomics and Proteomics and an HHMI Investigator, Dr. Eisenberg leads significant research initiatives in protein structure and aggregation. His laboratory combines X-ray crystallography, bioinformatics, and biochemical techniques to investigate protein interactions, with particular emphasis on amyloid-forming proteins and their role in disease. The Eisenberg Lab, located in Boyer Hall at UCLA, maintains an active research program investigating the structural basis of protein aggregation. The lab continues to build on its landmark discoveries of amyloid structures while exploring new frontiers in understanding protein misfolding diseases and developing potential therapeutic interventions.

Simon Schäferمشاهده پروفایل

استاد

• Neuroscience
• Developmental Biology
• Stem Cell Research
• +۴ مورد دیگر

Prof. Dr. Simon Schäfer leads the Schäfer Lab at the Technische Universität München , focusing on engineering advanced organoid systems to study human brain development, disease modeling, and repair mechanisms. His work bridges stem cell biology, gene editing, and bioengineering to develop personalized therapies for brain disorders. Stem Cell & Organoid Technology Neurodevelopmental Mechanisms Neurodegenerative Disease Models Gene Editing & Neuroimmune Interactions Translational Neuroscience Recent research emphasizes brain organoid development, microglia phenotypes, and neurodevelopmental timing anomalies in autism. His team’s work also explores zika virus interactions with glioblastoma stem cells and neuronal plasticity in psychiatric disorders. Scientific awards and funding include support from the Deutsche Forschungsgemeinschaft (DFG), Brain & Behavior Research Foundation (BBRF), and Munich Cluster for Systems Neurology (SyNergy). Collaborations span institutions like the TUM Center for Organoid Systems. Advises 6 students (2 PhD, 1 MSc, 3 associated) Labs include Schäfer Lab, COS@TranslaTUM Contact: simon.schafer@tum.de

John A. Copland, IIIمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +۳ مورد دیگر

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

• Biomaterials
• Peripheral Nerve Injury
• Neuromuscular Modeling and Repair
• +۲ مورد دیگر

Suradip Das is a Research Assistant Professor in the Department of Neurosurgery at the Perelman School of Medicine, University of Pennsylvania, where he serves as a Senior Research Investigator. His work bridges neural engineering and regenerative medicine to address critical challenges in nerve and muscle repair. His academic training includes: B.Tech in Biotechnology from Heritage Institute of Technology (2010) PhD in Biosciences and Bioengineering from Indian Institute of Technology Guwahati (2016) Dr. Das specializes in biomaterials development , peripheral nerve injury models , neuromuscular interface engineering , and stem cell-based regeneration . His research pioneers innervated tissue-engineered muscle constructs, demonstrating how motor neurons and endothelial cells synergistically enhance skeletal myocyte maturation. He innovates custom mechanobioreactors that apply tensile forces to guide nanofiber alignment for optimal myofiber formation, significantly advancing volumetric muscle loss treatments. Analysis of his 15 most recent publications reveals a dominant focus on neuromuscular regeneration (75% of articles), with emerging exploration of psychedelic compounds in neural repair. His work consistently integrates human iPSC-derived models , multi-cellular co-cultures , and large-animal validation to address translational gaps. Key trends include optogenetic control of motor units (2023), porcine nerve injury models (2020), and the critical role of pre-innervation in creating pro-regenerative microenvironments (2020-2022). As a core member of the Cullen Lab, Dr. Das collaborates on developing biofabricated neural microtissues for delayed nerve fusion and rapid functional recovery. His research directly informs clinical strategies for peripheral nerve repair and muscle regeneration through rigorous mechanistic studies and innovative engineering solutions.

Xian Wuمشاهده پروفایل

استادیار

• Developmental Toxicology
• Stem Cell Models
• Neurotoxicology
• +۵ مورد دیگر

Xian Wu, Ph.D., serves as a Research Assistant Professor in the Department of Pharmacology & Toxicology at East Carolina University's Brody School of Medicine. Her research leverages human stem cell models to investigate developmental vulnerabilities to environmental contaminants in cardiovascular and neural systems, with emphasis on epigenetic mechanisms and disease modeling. Dr. Wu's academic credentials include: Ph.D. in Toxicology from the University of Georgia M.S. in Biomedicine from East China Normal University B.S. in Biotechnology from Anhui University Her postdoctoral training comprised a Fellowship at the National Institute of Environmental Health Sciences and an ORISE Fellowship at the U.S. Food and Drug Administration. Research focuses on creating human stem cell-derived organoid systems to model developmental toxicology, particularly examining cardiac and neural development under chemical exposure. The laboratory employs fluorescence reporter systems and RNA-seq to identify critical vulnerability windows during early development, with recent work targeting Parkinson's disease mechanisms through dopaminergic neuron models and cardiac fibrosis via advanced organoids. Methodological innovations include high-content imaging for neurogenesis quantification and epigenetic pathway analysis. Publication trends (2016-2025) demonstrate consistent advancement in stem cell-based toxicology testing, with increasing emphasis on micro/nanoplastics risk assessment, arsenic neurotoxicity mechanisms, and doxorubicin cardiotoxicity modeling. The work bridges environmental health, epigenetics, and regenerative medicine through interdisciplinary approaches. Scientific recognition includes: 2025 SPARC Award (ECU) 2024 Top Abstract Award (Developmental Origins of Health and Disease Society) 2024 NIEHS P30 Center Travel Award 2023 ECU Research and Creative Activity Award Dr. Wu actively mentors graduate researchers including Ph.D. candidate Cate Duncan and M.S. students Kamilah Muhammad and Bailey Skeen, alongside undergraduate Bryce Tilghman. Former trainees McKyrah Brown and Monica Cross completed honors theses in the laboratory. Current grants include ECU's SPARC Award funding stem cell model development for environmental contaminant testing. The BSOM 6S-11 laboratory maintains specialized capabilities in cardiac and cerebral organoid generation, fluorescence-based toxicity screening, and RNA-seq epigenetic analysis. Collaborative networks include the National Institute of Environmental Health Sciences and ECU's Center for Human Health and the Environment, supporting translational research on developmental vulnerability periods.

Andrew Bassettمشاهده پروفایل

پژوهشگر

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +۵ مورد دیگر

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

Anthony Brownمشاهده پروفایل

دانشیار

• Cancer Biology
• Wnt Signaling
• Stem Cells
• +۷ مورد دیگر

Anthony Brown is an Associate Professor in the Department of Cell and Developmental Biology at Weill Cornell Medical College, part of the Graduate School of Medical Sciences. He has been a faculty member since 1987 and currently serves as Director of the Office of Medical Student Research. Education: B.A. in Natural Sciences (Genetics), University of Cambridge, 1977 M.A., University of Cambridge, 1980 Ph.D. in Molecular Biology, University of Edinburgh, 1982 Postdoctoral Fellow, University of California, San Francisco (with Harold Varmus) Postdoctoral Fellow, University of Strasbourg (with Pierre Chambon) Dr. Brown's research focuses on the Wnt family of signaling proteins and their roles in tissue development, homeostasis, and cancer. His work has significantly advanced the understanding of both canonical and non-canonical Wnt pathways, particularly in breast and colorectal cancers. He has shown that Wnt signaling contributes to oncogenesis through mechanisms involving stem-like cells, epithelial-to-mesenchymal transition, and crosstalk with other signaling cascades such as TGFβ. His research employs diverse models including cell culture, organoids, mouse models, and patient-derived tissues. His recent publications reveal a strong emphasis on Wnt signaling in cancer stem cells, metastasis, and signal transduction mechanisms. Trends include the role of Wnt in tumor microenvironments, regulation of ribosomal DNA, and therapeutic targeting of multiple pathways simultaneously. His work frequently appears in high-impact journals such as PNAS, Cancer Research, and Development. Scientific Awards: Royal Society European Science Exchange Fellowship Medical Research Council (U.K.) Travelling Fellowship Cornell Scholars Award Andrew W. Mellon Teacher-Scientist Award Pew Scholar in the Biomedical Sciences Irma T. Hirschl Career Scientist Award WCM Awards for Teaching Excellence WCM Awards for Excellence in Medical Education Dr. Brown has been actively involved in grant-funded research, including as a Co-Investigator on the Clinical and Translational Science Center (UL1) grant awarded by the National Center for Advancing Translational Sciences (2022–2027). He collaborates with a broad network of co-investigators across disciplines. He also mentors students and contributes to medical education, reflecting his dual commitment to research and teaching. His laboratory investigates Wnt signaling mechanisms and their implications for cancer therapeutics.

Cathy Yeمشاهده پروفایل

دانشیار

• Tissue Engineering
• Biomaterials
• Biomechanics
• +۵ مورد دیگر

Professor Cathy Ye is an Associate Professor of Engineering Science at the University of Oxford and Director of the Oxford Centre for Tissue Engineering and Bioprocessing (OCTEB) . She is also a Fellow of Linacre College , with research focusing on Tissue Engineering , Biomaterials , and Bioreactor Design for regenerative applications. Her research spans in vitro cancer modeling , bone-cartilage interface development , and smart bioreactor systems for cell therapy. Current projects include SimCells for Cultured Meat under the Tissue Engineering group, supported by grants like the BBSRC award and EPSRC First Grant (EP/H021442/1). She teaches C10 Biosystem Modelling , C23/BME2 Tissue Engineering , and B17/BME1 Biomechanics while leading lab modules for the MSc in Biomedical Engineering. Her publications cover extracellular vesicle purification , antimicrobial biomaterials , and 3D tumor models , reflecting her interdisciplinary approach to biomedical engineering challenges.

Anita Rauchمشاهده پروفایل

استاد

• Medical Genetics
• Neurodevelopmental Disorders
• Genome Sequencing
• +۳ مورد دیگر

Anita Rauch is a Full Professor of Medical Genetics and Director of the Institute of Medical Genetics at the University of Zurich. Her research focuses on the genetic and molecular mechanisms underlying severe neurodevelopmental disorders and hereditary breast cancer, utilizing genome sequencing and human induced pluripotent stem cell (iPSC) models. Current projects include: Genetic causes and molecular mechanisms in severe intellectual disability Praeclare (genetic variant clarification for prenatal medicine) SwissGenVar (clinical genetic variant interpretation platform) Hereditary breast cancer in Switzerland Her work is funded by the Swiss National Science Foundation (SNSF). She leads a multidisciplinary team conducting functional studies on novel candidate genes (e.g., CYFIP2, TMEM94) and exploring genotype-phenotype correlations through iPSC-derived neuronal models. Key research trends in her publications include: Clinical trials for cancer therapies (colon, esophageal, pancreatic, breast) Pharmacogenetic determinants of chemotherapy toxicity Non-inferiority trial design methodology Genetic variant interpretation in personalized medicine She mentors PhD and Master’s students in medical genetics and contributes to the advancement of precision oncology and neurogenetics through translational research.

Pam J. McLeanمشاهده پروفایل

استاد

• Neurodegenerative Diseases
• Parkinson's Disease
• Dementia with Lewy Bodies
• +۱۲ مورد دیگر

Pam J. McLean, Ph.D. is a Professor of Neuroscience and Consultant in the Department of Neuroscience at Mayo Clinic, Jacksonville, Florida . She leads the Neurobiology of Parkinson's Disease and Related Disorders Laboratory , focusing on the molecular mechanisms of neurodegenerative diseases such as Parkinson’s disease and dementia with Lewy bodies. Primary Appointment: Consultant, Department of Neuroscience Institution: Mayo Clinic, Jacksonville, FL Research Affiliations: APDA Center for Advanced Research, Center for Clinical and Translational Science (CCaTS), Discovery and Translation Labs: Brain Research, Lewy Body Dementia Center Without Walls Dr. McLean’s research centers on alpha-synuclein , a key protein involved in neurodegeneration. Her lab investigates how alpha-synuclein misfolds, aggregates, and propagates in a prion-like manner across neurons, contributing to disease progression. She employs human induced pluripotent stem cell models, viral vector-based systems, and animal models to study these processes. Key research themes include: Prion-like propagation of alpha-synuclein Biomarker discovery using extracellular vesicles in blood Copathologies in neurodegenerative diseases Development of gene therapies and small molecules targeting alpha-synuclein Her recent publications highlight work on alpha-synuclein seeding assays, transcriptional differences between Lewy body disease and Alzheimer’s, and novel methods for isolating plasma-derived extracellular vesicles for diagnostic use. These reflect a strong trend toward translational neuroscience, aiming to bridge molecular insights with clinical applications. Dr. McLean is actively funded through multiple NIH grants, including from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke. She serves as Principal Investigator on projects related to functional assessment of pathological species in Lewy body dementia and contributes to the Mayo Alzheimer’s Disease Research Center. Her lab is committed to patient-centered research and training the next generation of neuroscientists, offering postdoctoral fellowships and research education programs. She collaborates extensively with experts in neuropathology, neurology, and translational biology.

Zhengqing Huمشاهده پروفایل

استاد

• Hearing Loss Treatment
• Stem Cell Biology
• Auditory Neuroscience
• +۳ مورد دیگر

Dr. Zhengqing Hu is a tenured, full-time Professor in the Department of Otolaryngology – Head and Neck Surgery at Wayne State University School of Medicine. He holds joint appointments in the Department of Physiology/Cell Biology and has active research programs in stem cell-based hearing restoration. Dr. Hu's academic journey includes dual MD and PhD training in China, a second PhD at Karolinska Institute, Sweden, and postdoctoral work at the University of Virginia. Education : MD from Shanghai Medical University, PhD in neurotology from China, second PhD in cell replacement therapy at Karolinska Institute Grants : NIH R01, DoD grants, VA SPiRE, and Wayne State OVPR funding His research focuses on auditory synapse regeneration , epigenetic reprogramming for hair cell repair, and development of biological hearing restoration models . The Hu lab employs stem cell biology, in vitro and in vivo transplantation, advanced microscopy, and electrophysiology to investigate inner ear progenitor cell differentiation and neural integration. Recent publications highlight DNA demethylation strategies for hair cell regeneration and auditory neuron synaptogenesis. Dr. Hu serves on multiple NIH, VA, and international grant review panels. He teaches graduate courses in Stem Cell Biology , Molecular Physiology , and Cell Biology at Wayne State University, including directing the Embryonic Stem Cell Biology course. His lab's work aims to establish a Biological-EAR model for future hearing loss treatments.

Bianxiao Cuiمشاهده پروفایل

استاد

• Biophysics
• Cell Biology
• Chemistry
• +۶ مورد دیگر

Professor Bianxiao Cui is the Job and Gertrud Tamaki Professor of Chemistry at Stanford University and a fellow of the Wu Tsai Stanford Neuroscience Institute. Her research integrates biophysics, cell biology, chemistry, and nanotechnology to develop tools for studying the nano-bio interface, membrane curvature, electrophysiology, and signal transduction in health and disease. Ph.D. in Chemistry, University of Chicago (2002) B.S. in Material Science & Engineering, University of Science & Technology of China (1998) Her group bridges biochemistry, material science, and neuroscience to probe cellular processes at nanoscale. Key projects include: Mechanisms of Membrane Curvature: How nanoscale topography regulates integrin adhesions, ER-PM contacts, and ion channel activity. Electrophysiological Tools: Nanoelectrode arrays (NEAs) and electrochromic optical recording (ECORE) for scalable, label-free action potential monitoring. Protein Relocalization: Using shuttle proteins to rewire subcellular localization for disease intervention. Recent articles highlight advancements in 3D cell adhesion , AI-driven electrophysiology , and optogenetic pain models . Her work spans biochemical assays, nanofabrication, and in vivo studies . Scientific Awards: Ono Pharma Breakthrough Science Initiative Award (2022-2025) NIH New Innovator Award (2012-2017) NSF CAREER and INSPIRE Awards Packard and Searle Fellowships Teaching & Advising: She mentors PhD students in Chemistry and Biophysics, including Krishna Raghavan and Pengwei Sun , and supervises postdoctoral fellows like Dr. Wei Zhang . She teaches Biophysical Chemistry and advises on cellular nanomechanics and optogenetics . Labs & Collaborations: The Cui Lab collaborates with the Melosh and Khosla labs, focusing on cell-material interactions and neurotechnology development (e.g., Kirigami electronics for organoid stimulation).

• Autophagy
• Lysosomes
• Neuroinflammation
• +۵ مورد دیگر

Marta Lipinski is an Associate Professor in the Department of Anesthesiology at the University of Maryland School of Medicine . She is also affiliated with the Shock, Trauma and Anesthesiology Research (STAR) Center , the Center for Stem Cell Biology and Regenerative Medicine , and the Center for Biomolecular Therapeutics . Her research focuses on the role of autophagy and lysosomal function in neurotrauma and neurodegenerative diseases . PhD in Cancer Biology, MIT Postdoctoral training at Harvard Medical School Her research keywords include Autophagy , Lysosomes , Neuroinflammation , Lipid Metabolism , Traumatic Brain Injury , Spinal Cord Injury , and Brain Aging . She investigates how autophagy disruption after CNS injury contributes to neuroinflammation and neuronal death , with recent work exploring the link between TBI and late-onset neurodegeneration as well as autophagy-lipid metabolism interactions . Her collaborative network spans departments and institutions, including Junfang Wu (Anesthesiology), Eugene Koh (Orthopaedics), Maureen Kane (School of Pharmacy), and Michael Cummings (UMD College Park). Active grants include NIH R33 AG076858 and R01 NS115876 , focusing on multi-omics platforms for brain aging and autophagy modulation in TBI.

• Research Methods
• Pathology
• Molecular Biology
• +۷ مورد دیگر

Dr. Faith Kwa is a Senior Lecturer and Course Director for the seven Bachelor of Health Science degrees at Swinburne University of Technology's School of Health Sciences. Her teaching interests include Research Methods, Pathology, and Molecular Biology. She leads the Drug Discovery for Chronic Diseases Laboratory and has been recognized as one of Australia's leading educators, receiving the 2024 citation for Outstanding Contributions to Student Learning by the Australian Awards for University Teaching. Her educational background includes: Doctor of Philosophy from The University of Melbourne, Australia Graduate Certificate in Tertiary Teaching and Learning from RMIT University, Australia Bachelor of Biomedical Science from The University of Melbourne, Australia Bachelor of Science (Honours - First Class) from The University of Melbourne, Australia Fellow of the Higher Education Academy, United Kingdom (2020-present) Dr. Kwa is a molecular biologist whose research focuses on drug discovery for chronic diseases, particularly in the areas of epigenetic medicine, molecular mechanisms of action, and chronic disease prevention and management. Her laboratory has made significant contributions to understanding treatment strategies for leukemia, posterior eye diseases, and Friedreich's ataxia using natural compounds with epigenetic properties. She has made novel observations regarding low doses of epigenetic modifiers in combination therapies that potentiate cytotoxicity in leukemia cells resistant to conventional chemotherapeutic drugs. Her work with sulforaphane (a broccoli-derived compound) has shown therapeutic benefits across multiple disease models, particularly for neurodegenerative and ocular conditions. Analysis of her recent publications reveals a strong focus on neurodegenerative disorders (particularly Friedreich's ataxia), ophthalmic diseases, and molecular approaches to disease treatment. Her work consistently bridges basic science with clinical applications, often examining epigenetic mechanisms and oxidative stress pathways. A recurring theme across her research is the therapeutic potential of natural compounds like sulforaphane, which appears in multiple disease contexts from mitochondrial myopathies to posterior eye diseases. Her scientific recognition includes: 2024 citation for Outstanding Contributions to Student Learning by the Australian Awards for University Teaching 2023 Vice-chancellor's Award for Teaching Excellence (Higher Education - Individual) 2023 School of Health Science Teaching Excellence Award Fellow of the Higher Education Academy in the UK 18 other teaching accolades throughout her academic career Dr. Kwa supervises PhD and Master's students in areas related to molecular mechanisms of disease and therapeutic interventions. She has coordinated and taught eleven different subjects with student numbers ranging from 20 to over 300. As a Chief Investigator, she has secured various learning and teaching grants from Australian universities. Currently, she holds funding for 'Pre-clinical investigations on sulforaphane to advance the cure for Friedreich's ataxia' from the University of Melbourne (2022-2025). She is passionate about developing pedagogical methods to enhance teaching and learning environments and has received positive student feedback throughout her career. Dr. Kwa leads the Drug Discovery for Chronic Diseases Laboratory, where her team investigates potential treatments for various chronic disorders. She also serves as the Swinburne Women Academic Network Leader in the Career Development Team, where she develops programs supporting women academics in progressing their careers. Her laboratory work utilizes pre-clinical disease models to evaluate therapeutic approaches, with a particular emphasis on targeted therapies with superior efficacy for treating human diseases.